MusclePharm (MusclePharm) COGS-to-Revenue : 0.88 (As of Mar. 2022)

View and export this data going back to 2008. Start your Free Trial

What is MusclePharm COGS-to-Revenue?

MusclePharm's Cost of Goods Sold for the three months ended in Mar. 2022 was $11.59 Mil. Its Revenue for the three months ended in Mar. 2022 was $13.10 Mil.

MusclePharm's COGS to Revenue for the three months ended in Mar. 2022 was 0.88.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. MusclePharm's Gross Margin % for the three months ended in Mar. 2022 was 11.52%.

MusclePharm COGS-to-Revenue Historical Data

The historical data trend for MusclePharm's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MusclePharm COGS-to-Revenue Chart

MusclePharm Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

COGS-to-Revenue

Get a 7-Day Free Trial

0.70

0.79

0.89

0.70

0.89

MusclePharm Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
COGS-to-Revenue	Get a 7-Day Free Trial															0.72	0.85	1.00	1.05	0.88

MusclePharm COGS-to-Revenue Calculation

MusclePharm's COGS to Revenue for the fiscal year that ended in Dec. 2021 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	44.671	/	50.042
	=	0.89

MusclePharm's COGS to Revenue for the quarter that ended in Mar. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	11.592	/	13.101
	=	0.88

MusclePharm (OTCPK:MSLPQ) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

MusclePharm's Gross Margin % for the three months ended in Mar. 2022 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	11.592 / 13.101
	=	11.52 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

MusclePharm COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of MusclePharm's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

MusclePharm (MusclePharm) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » MusclePharm Corp (OTCPK:MSLPQ) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

6728 W. Sunset Road, Suite 130, Las Vegas, NV, USA, 89118

Website

https://www.musclepharmcorp.com

MusclePharm Corporation is a performance lifestyle company. It develops, manufactures, markets and distributes branded nutritional supplements. It offers various types of powders, capsules, tablets and gels. Geographically, the firm has its business presence across the region of US and in the international market of which the US accounts for the majority of revenue. MusclePharm's Hybrid series products include Assault, Combat Protein Powder, BCAA 3:1:2, CLA Core, Fish Oil, Combat Crunch Protein Bars, glutamine, carnitine, Combat Crunch, Protein Crisp, Organic Protein, and Protein Cookie. The group sells its products to various fitness enthusiasts, such as professional, combat sport, weight training, bodybuilding, running, and various team and individual sports, and others.

Executives

Eric Chin	officer: Chief Accounting Officer	1668 S. GARFIELD AVE., 2ND FLOOR, ALHAMBRA CA 91801
Paul W Karr	director	BRISTOL MEYERS SQUIBB CO, 345 PARK AVENUE, NEW YORK NY 10154
Sabina Rizvi	officer: President & CFO	6728 W. SUNSET ROAD, SUITE 130, LAS VEGAS NV 89118
Michael David Heller	director	4500 PARK GRANADA, SUITE 202, CALABASAS CA 91302
Wynnefield Partners Small Cap Value Lp I	10 percent owner	450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Donald Feagan	10 percent owner	2150 SOUTH 1300 EAST STREET, SUITE 500, SALT LAKE CITY UT 84106
Amerop Holdings, Inc.	10 percent owner	1800 BROADWAY, SUITE 100, BOULDER CO 80302
White Winston Select Asset Fund Series Fund Mp-18, Llc	10 percent owner	C/O WHITE WINSTON SELECT ASSET FUNDS, LLC, 265 FRANKLIN ST., SUITE 1702, BOSTON MA 02110
Robert P Mahoney	10 percent owner	4 DANIELS FARM ROAD, #305, TRUMBULL CT 06611
White Winston Select Asset Funds, Llc	10 percent owner	265 FRANKLIN STREET, SUITE 1702, BOSTON MA 02110
Todd M. Enright	10 percent owner	2150 SOUTH 1300 EAST STREET, SUITE 500, SALT LAKE CITY UT 84106
Mark Blundell	10 percent owner	8 MACDONALD AVE, ARMOUK NY 10504
John J Desmond	director	10 GLEN HEAD ROAD, GLEN HEAD NY 11545
Wynnefield Small Cap Value Offshore Fund Ltd	10 percent owner	450 SEVENTH AVE, STE 509, NEW YORK NY 10123
Wynnefield Capital Inc	10 percent owner	450 SEVENTH AVE, STE 509, NEW YORK NY 10123